Opcjonalna analityka produktu
Za zgodą użytkownika stosujemy ograniczoną analitykę chroniącą prywatność, aby zrozumieć, które ścieżki badawcze działają. Nie używamy trackerów reklamowych ani nagrywania sesji. Ten wybór można zmienić w Preferencjach. Przeczytaj Politykę prywatności.
Charles River Laboratories International Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $13.4B | |
|---|---|---|
| Revenue (ttm) | 4B | |
| Net income (ttm) | -238.5M | |
| EPS (ttm) | -$4.88 | |
| Shares out | 47.7M | |
| P/E (forward) | 22.5x | |
| Volume | 1,085,812 | |
| Beta | 1.40 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-25 | 2022-12-31 | 2023-12-30 | 2024-12-28 | 2025-12-27 | Trend |
| Revenue | $3.54B | $3.98B | $4.13B | $4.05B | $4.02B | +3.2% |
| Gross profit | $1.33B | $1.46B | $1.50B | $1.33B | $1.23B | -2.1% |
| Operating income | $589.9M | $651.0M | $617.3M | $227.3M | $25.2M | -54.6% |
| Net income | $391.0M | $486.2M | $474.6M | $22.2M | $-144.3M | — |
| EPS (diluted) | $7.60 | $9.48 | $9.22 | $0.20 | $-2.91 | — |
| EBITDA | $820.2M | $986.1M | $1.03B | $581.1M | $410.8M | -15.9% |
| R&D | — | — | — | — | — | — |
| SG&A | $619.9M | $665.1M | $747.9M | $751.0M | $743.1M | +4.6% |
Recent company headlines from major financial publishers.
Under the base scenario, which carries a probability of 45.0%, biopharmaceutical preclinical study demand stabilizes following near-term budget austerity, and operational restructuring in Manufacturing Support eliminates segment operating losses. Normalized consolidated operating margins expand steadily toward peer benchmarks, driving the equity valuation to $367.67, representing an expected return of 32.2% relative to $278.06. This path is disconfirmed if early-stage biotechnology study cancellations accelerate or if fixed facility costs prevent margin expansion over the next several fiscal quarters.
In the bull scenario, assigned a probability of 25.0%, a decisive recovery in global biopharma venture funding spurs candidate progression into IND-enabling toxicology studies. Discovery and Safety Assessment study volume re-accelerates sharply, allowing substantial fixed-cost operating leverage to drive consolidated margins above peer benchmarks. Combined with a successful turnaround in Manufacturing Support and rapid debt repayment, equity value reaches Potential value of $459.24, delivering a return of 65.2% from $278.06. Investors would confirm this trajectory through sequential quarterly revenue growth re-acceleration and expanding backlog over the next year.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 7.9% | $142 | $142 | $142 | $142 | $142 |
| 8.9% | $137 | $137 | $137 | $137 | $137 |
| 9.9% | $131 | $131 | $131 | $131 | $131 |
| 10.9% | $126 | $126 | $126 | $126 | $126 |
| 11.9% | $122 | $122 | $122 | $122 | $122 |
Upcoming earnings date and setup when available.
Rekomendacja, którą nosiło opublikowane w danym miesiącu wydanie analizy. Rekomendacja porównuje cenę z dnia analizy z wartością godziwą; nie jest zapisem tego, czy ocena się sprawdziła.
| Rok | sty | lut | mar | kwi | maj | cze | lip | sie | wrz | paź | lis | gru |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
